TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

C4 Therapeutics Inc (CCCC)

Healthcare Biotechnology
3.50 $
-4.9% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns C4 Therapeutics Inc (CCCC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.7% of the shares are freely tradable; institutional investors hold 85.1%.

Ownership Structure

Institutional ownership
85.1%
Insiders
1.1%
Float
75.7%
Short % of float
21.7%
Shares Outstanding
111Mio.

Largest Shareholders

Institutions

Institutions CCCC
Name Stake (%) Shares Change (%) Date
Morgan Stanley - Brokerage Accounts 8.21 9,072,400 +1.0 03/31/2026
RA Capital Management, LLC 7.24 8,000,000 +0.0 03/31/2026
Bain Capital Life Sciences Investors, LLC 6.49 7,171,910 +0.0 03/31/2026
Lynx1 Capital Management, LP 6.33 6,998,902 -1.4 03/31/2026
Vanguard Capital Management, LLC 3.49 3,861,852 +0.0 03/31/2026
Soleus Capital Management, L.P. 3.44 3,803,942 +0.0 03/31/2026
Wasatch Advisors LP 3.19 3,522,644 +18.9 06/30/2026
JPMorgan Chase & Co 2.92 3,223,054 +54,114.5 03/31/2026
Two Sigma Investments LLC 2.75 3,035,634 +101.1 03/31/2026

Funds

Funds CCCC
Name Stake (%) Shares Change (%) Date
Vanguard Morn Total Stk Mkt Idx Investor 2.95 3,264,924 +12.9 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
10. Jul 2026 Reyno Leonard Chief Medical Officer Other 7,397 4.06 30,032
10. Jul 2026 Reyno Leonard Chief Medical Officer Other 15,325 0.00

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?